These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15230300)

  • 1. Clinical trial design in systemic lupus erythematosus: lessons learned and future directions.
    Strand V
    Lupus; 2004; 13(5):406-11. PubMed ID: 15230300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome measures to be used in clinical trials in systemic lupus erythematosus.
    Strand V; Gladman D; Isenberg D; Petri M; Smolen J; Tugwell P
    J Rheumatol; 1999 Feb; 26(2):490-7. PubMed ID: 9972993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care.
    Castrejón I; Tani C; Jolly M; Huang A; Mosca M
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-85-95. PubMed ID: 25365095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons learned from clinical trials in SLE.
    Strand V
    Autoimmun Rev; 2007 Mar; 6(4):209-14. PubMed ID: 17317609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity.
    American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria
    Arthritis Rheum; 2004 Nov; 50(11):3418-26. PubMed ID: 15529383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trial design in systemic lupus erythematosus.
    Dall'Era M; Wofsy D
    Curr Opin Rheumatol; 2006 Sep; 18(5):476-80. PubMed ID: 16896285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do?
    Schiffenbauer J; Simon LS
    Lupus; 2004; 13(5):398-405. PubMed ID: 15230299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort.
    Inês L; Silva C; Galindo M; López-Longo FJ; Terroso G; Romão VC; Rúa-Figueroa I; Santos MJ; Pego-Reigosa JM; Nero P; Cerqueira M; Duarte C; Miranda LC; Bernardes M; Gonçalves MJ; Mouriño-Rodriguez C; Araújo F; Raposo A; Barcelos A; Couto M; Abreu P; Otón-Sanchez T; Macieira C; Ramos F; Branco JC; Silva JA; Canhão H; Calvo-Alén J; ;
    Arthritis Care Res (Hoboken); 2015 Aug; 67(8):1180-5. PubMed ID: 25581417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of rheumatoid arthritis and systemic lupus erythematosus trial design: a commentary on ways to improve the number of positive trials in SLE.
    Miles A; Pope JE
    Clin Exp Rheumatol; 2015; 33(5):671-80. PubMed ID: 26315693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measuring outcomes in systemic lupus erythematosus clinical trials.
    Strand V; Chu AD
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):455-68. PubMed ID: 21831027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of clinical manifestations, disease activity and organ damage in 996 Korean patients with systemic lupus erythematosus: comparison with other Asian populations.
    Joo YB; Bae SC
    Int J Rheum Dis; 2015 Feb; 18(2):117-28. PubMed ID: 25524656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
    Mok CC; Ho LY; Cheung MY; Yu KL; To CH
    Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future--the EULAR recommendations for the management of SLE and the use of end-points in clinical trials.
    Bertsias G; Gordon C; Boumpas DT
    Lupus; 2008 May; 17(5):437-42. PubMed ID: 18490423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.
    Hanly JG; McCurdy G; Fougere L; Douglas JA; Thompson K
    J Rheumatol; 2004 Nov; 31(11):2156-62. PubMed ID: 15517627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus.
    Nived O; Jönsen A; Bengtsson AA; Bengtsson C; Sturfelt G
    J Rheumatol; 2002 Jul; 29(7):1398-400. PubMed ID: 12136895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcome of early neuropsychiatric events due to active disease in systemic lupus erythematosus.
    Wang M; Gladman DD; Ibañez D; Urowitz MB
    Arthritis Care Res (Hoboken); 2012 Jun; 64(6):833-7. PubMed ID: 22290935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lupus headaches in childhood-onset systemic lupus erythematosus: relationship to disease activity as measured by the systemic lupus erythematosus disease activity index (SLEDAI) and disease damage.
    Brunner HI; Jones OY; Lovell DJ; Johnson AM; Alexander P; Klein-Gitelman MS
    Lupus; 2003; 12(8):600-6. PubMed ID: 12945718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality of life in portuguese SLE patients: an outcome measure independent of disease activity and cumulative damage.
    Duarte C; Abreu P; Couto M; Vaz C; Malcata A; Inês L
    Acta Reumatol Port; 2010; 35(1):30-5. PubMed ID: 20518146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.